These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6704502)

  • 1. Preliminary observations on dissolution and bioavailability of triamterene-hydrochlorothiazide combination products.
    Shah VP; Walker MA; Prasad VK; Lin J; Knapp G; Cabana BE
    Biopharm Drug Dispos; 1984; 5(1):11-9. PubMed ID: 6704502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [On the bioavailability of hydrochlorothiazide and triamterene from commercial drugs (author's transl)].
    Knauf H; Möhrke W; Mutschler E; Völger KD
    Arzneimittelforschung; 1980; 30(6):1001-4. PubMed ID: 7191258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro/in vivo evaluation of hydrochlorothiazide in experimental hydrochlorothiazide/triamterene combination tablets in beagle dogs.
    Ritschel WA; Turkoglu M; Lipps D; Warner A; Sakr A
    Arzneimittelforschung; 1991 Mar; 41(3):208-11. PubMed ID: 1867656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered.
    Upton RA; Williams RL; Lin ET; Gee WL; Blume CD; Benet LZ
    J Pharmacokinet Biopharm; 1984 Dec; 12(6):575-86. PubMed ID: 6533293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new antihypertensive agent: Maxzide (75 mg triamterene/50 mg hydrochlorothiazide).
    Blume CD; Williams RL
    Am J Med; 1984 Nov; 77(5A):52-8. PubMed ID: 6388327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence study of a new tablet formulation of triamterene and hydrochlorothiazide.
    Blume CD; Williams RL; Upton RA; Lin ET; Benet LZ
    Am J Med; 1984 Nov; 77(5A):59-61. PubMed ID: 6496560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.
    Möhrke W; Knauf H; Mutschler E
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):447-52. PubMed ID: 9352394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and bioequivalence of a brand-name and a generic triamterene-hydrochlorothiazide combination product.
    Sharoky M; Perkal M; Tabatznik B; Cane RC; Costello K; Goodwin P
    Clin Pharm; 1989 Jul; 8(7):496-500. PubMed ID: 2752698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypotensive effect of hydrochlorothiazide and its combination with triamterene].
    Levinzon AM; Glezer GA
    Sov Med; 1989; (6):5-8. PubMed ID: 2678520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a fixed combination with propranolol, hydrochlorothiazide and triamterene.
    Felder K; Geissler HE; Hiemstra S; Mutschler E; Schäfer M; Ziegler E
    Arzneimittelforschung; 1979; 29(11):1746-52. PubMed ID: 543886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function.
    Williams RL; Thornhill MD; Upton RA; Blume C; Clark TS; Lin E; Benet LZ
    Clin Pharmacol Ther; 1986 Aug; 40(2):226-32. PubMed ID: 3731685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption and disposition of a new low-dose combination formulation of hydrochlorothiazide and triamterene.
    Williams RL; Lin ET; Liang-Gee W; Blume CD; Benet LZ
    Biopharm Drug Dispos; 1990 Apr; 11(3):233-43. PubMed ID: 2328310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral triamterene disposition.
    Sörgel F; Hasegawa J; Lin ET; Williams RL
    Clin Pharmacol Ther; 1985 Sep; 38(3):306-12. PubMed ID: 4028626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.
    Schuster O; Loew D; Knoell HE
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):127-32. PubMed ID: 4043142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined eutexia and amorphization for simultaneous enhancement of dissolution rate of triamterene and hydrochlorothiazide: preparation of orodispersible tablets.
    Awad HA; Fetouh MI; Sultan AA; El Maghraby GM
    Drug Dev Ind Pharm; 2024 Apr; 50(4):306-319. PubMed ID: 38400841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of bemetizide and triamterene from a combination formulation.
    Brodie RR; Chasseaud LF; Darragh A; Taylor T; Walmsley LM
    Biopharm Drug Dispos; 1982; 3(4):361-70. PubMed ID: 7159690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of the hypotensive action of monotherapy using hydrochlorothiazide and its combination with triamterene and amiloride and their effect on hemodynamics at rest and during exercise therapy].
    Glezer GA; Lipko DS; Levinzon AM
    Kardiologiia; 1990 Jul; 30(7):11-3. PubMed ID: 2232453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bioavailability and pharmacokinetics of hydrochlorothiazide from oral tablet dosage forms, determined by plasma level and urinary excretion methods.
    Barbhaiya RH; Patel RB; Corrick-West HP; Joslin RS; Welling PG
    Biopharm Drug Dispos; 1982; 3(4):329-36. PubMed ID: 7159688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence evaluation of a triamterene-hydrochlorothiazide generic product: a new bioequivalence index for fixed-dose combinations.
    Hamidi M; Shahbazi MA; Azimi K
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):149-56. PubMed ID: 21193005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative study of potassium-sparing effects of triamterene and amiloride in the treatment with hydrochlorothiazide].
    Glezer GA; Merzon AK; Lipko DS; Donskova TV; Levinzon AM; Shelest IuP
    Klin Med (Mosk); 1990 Sep; 68(9):61-4. PubMed ID: 2290332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.